Sunnybrook Health Sciences Centre
sunnybrook.caLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
577
Active
155
Phase 3
39
Total enrollment
1,376,000
Pipeline matrix
Showing 40 of 50 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexmedetomidine Hydrochloride Group | — | — | — | — | — | 2 | |
| Glucocorticoid | — | — | — | — | — | 1 | |
| Duloxetine | — | — | — | — | 3 | ||
| Isoflurane Inhalant Product | — | — | — | — | — | 2 | |
| Normal saline | — | — | — | — | 3 | ||
| Tranexamic acid | — | — | — | — | 3 | ||
| Nabilone | — | — | — | — | — | 2 | |
| Ketamine | — | — | — | — | 2 | ||
| Edoxaban 15 mg | — | — | — | — | — | 1 | |
| Aspirin or clopidogrel | — | — | — | — | — | 1 | |
| modified PENTOCLO | — | — | — | — | — | 1 | |
| sham mPENTOCLO | — | — | — | — | — | 1 | |
| Eptinezumab | — | — | — | — | — | 1 | |
| Dalteparin | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | — | 1 | |
| Sevoflurane inhalant product | — | — | — | — | — | 1 | |
| Definity | — | — | — | — | 3 | ||
| Methylphenidate | — | — | — | 3 | |||
| Rituximab | — | — | — | — | — | 2 | |
| Sodium Thiosulfate + Mannitol | — | — | — | — | — | 1 | |
| Acalabrutinib | — | — | — | — | — | 1 | |
| Bendamustine | — | — | — | — | — | 1 | |
| QBECO | — | — | — | — | — | 1 | |
| Enzalutamide Dose Escalation | — | — | — | — | — | 1 | |
| Standard of Care | — | — | — | — | — | 1 | |
| Daily TMZ | — | — | — | — | — | 1 | |
| Hormone therapy | — | — | — | — | — | 1 | |
| Niraparib | — | — | — | — | — | 1 | |
| Tucatinib 150 MG | — | — | — | — | — | 1 | |
| Trastuzumab | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | — | 1 | |
| Levetiracetam | — | — | — | — | — | 1 | |
| CBD | — | — | — | — | — | 1 | |
| Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension | — | — | — | — | — | 2 | |
| Definity Suspension for | — | — | — | — | — | 2 | |
| Hyperpolarized 13C-Pyruvate | — | — | — | — | — | 2 | |
| Intravenous immunoglobulin (IVIG), 10% solution for | — | — | — | — | — | 1 | |
| Olaparib | — | — | — | — | — | 1 | |
| Navitoclax | — | — | — | — | — | 1 |
10 more active programs hidden
Next readouts
- 2022-08
- 2024-05-31
- 2025-03-30
- 2025-07-11
- 2025-09
- 2025-12-31
- 2026-02-01
- 2026-03-01
- 2026-03-31
- 2026-05
Top conditions
- Breast Cancer30
- Prostate Cancer26
- Stroke14
- Depression12
- Hypertension11
- Major Depressive Disorder10
- Obsessive-Compulsive Disorder10
- Alzheimer Disease10
Frequently asked questions about Sunnybrook Health Sciences Centre
- How many clinical trials does Sunnybrook Health Sciences Centre have on ClinicalTrials.gov?
- Sunnybrook Health Sciences Centre is listed as the lead sponsor on 577 clinical trials in ClinicalTrials.gov, 155 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sunnybrook Health Sciences Centre's trials are in Phase 3?
- 39 of Sunnybrook Health Sciences Centre's trials are in Phase 3, spread across 50 active drug programs.
- What therapeutic areas does Sunnybrook Health Sciences Centre focus on?
- Sunnybrook Health Sciences Centre's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Stroke, Depression, Hypertension.
- When are Sunnybrook Health Sciences Centre's next clinical trial readouts?
- Sunnybrook Health Sciences Centre has 10 upcoming primary-completion readouts tracked here; the soonest is “The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial”, expected around 2022-08.